Patent intelligence · EP
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
Patent details — EP 3708579
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Sep 16, 2020
- Expiration
- Sep 11, 2040
- Applicant
- BIONTECH CELL & GENE THERAPIES GMBH [DE]
- CPC classes
- A61K 35/ 26 A I, A61K/4011, A61K/4031, A61K/4032
Quick answer
EP 3708579 (CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE) is held by BIONTECH CELL & GENE THERAPIES GMBH [DE]. Status: granted. Granted Sep 16, 2020. Expires Sep 11, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIONTECH CELL & GENE THERAPIES GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 35/ 26 A I, A61K/4011, A61K/4031, A61K/4032, A61K/404202, A61K/40428
More from BIONTECH CELL & GENE THERAPIES GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 3708579?
EP 3708579 (CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE) is held by BIONTECH CELL & GENE THERAPIES GMBH [DE]. Status: granted. Granted Sep 16, 2020. Expires Sep 11, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 3708579?
BIONTECH CELL & GENE THERAPIES GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 3708579 expire?
Our index shows an expiration date of Sep 11, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.